Imifoplatin
Tier C — Watch / tradeImifoplatin
Targets：DNA
Indications (approved)：胸腺瘤, 胸腺上皮肿瘤, 胸腺肿瘤, Solid tumour, Non-small cell lung cancer, Hepatocellular carcinoma, Genitourinary neoplasm, 男性生殖器官肿瘤
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| PT-112 | 1109292-06-9 | PT-112 |
| PT-112-001 | 38780-40-4 | - |
Frequently asked questions
What are the approved indications of Imifoplatin?
Approved indications include: 胸腺瘤, 胸腺上皮肿瘤, 胸腺肿瘤, Solid tumour, Non-small cell lung cancer, Hepatocellular carcinoma, Genitourinary neoplasm, 男性生殖器官肿瘤.
When does the Imifoplatin patent expire?
No public expiry year is available for Imifoplatin yet; this page updates once verified.
How many synthesis routes are recorded for Imifoplatin?
1 synthesis routes are recorded; the shortest is 1 steps with 0.07 g total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Imifoplatin intermediates?
All intermediates in Imifoplatin routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Imifoplatin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-12